The Relationship between PTPN22 R620W Polymorphisms and the Susceptibility to Autoimmune Thyroid Diseases: An Updated Meta-analysis

ABSTRACT

The protein tyrosine phosphatase non-receptor 22 (PTPN22) R620W polymorphism has been related to susceptibility to autoimmune thyroid disease (AITD) with inconsistent results. Therefore, this meta-analysis was designed to assess a more accurate association between the PTPN22 R620W polymorphism and AITD susceptibility. A systematic search of the EMBASE, PubMed, Web of Science, CBM, CNKI, and WanFang databases was performed to determine relevant publications. Statistical analyses of the odds ratios (ORs), 95% confidence intervals (CIs), and p values were performed using STATA software. Our meta-analysis included 18 separate studies comprised of 4,726 cases and 4,220 controls. In the allele and all genetic models, PTPN22 R620W polymorphism and Graves’ disease (GD) (allele model TvsC: OR = 1.573; 95% CI = 1.378–1.795; P < .001) and Hashimoto’s thyroiditis (HT) (allele model TvsC: OR = 1.737; 95% CI = 1.230–2.454; P = .002) susceptibility was positively associated. A racial subgroup analysis showed that the T allele significantly increased AITD susceptibility in all genetic models involving Caucasians, but not in Asians. This meta-analysis showed that the PTPN22 R620W polymorphism is associated with the risk of GD and HT in the overall study population. In addition, the PTPN22 R620W polymorphism is associated with elevated AITD risk in Caucasians, but not in Asians.

KEYWORDS:

• autoimmune thyroid diseases
• Graves’ disease
• Hashimoto’s thyroiditis
• protein tyrosine phosphatase nonreceptor 22
• polymorphism

Disclosure statement

This article does not contain any studies with human participants or animals performed by any of the authors. The authors declare no conflicts of interest.

Additional information

Funding

This study was supported by grants from the National Natural Science Foundation of China [81872561].